Evidence Hub

Limited Role of Mycoplasma genitalium, Chlamydia trachomatis, and Neisseria gonorrhoeae in Pelvic Inflammatory Disease and Tubo-Ovarian Abscess in the Netherlands: A Multicenter Prospective Cohort Study

Adriaens N, Bruisten SM, Vergunst CE, Jongen VW, Braam JF, Nijhuis RHT, Bukman A, van Kesteren PJM et al.

Obstetrics and gynecology international, 2026

100 participants

Abstract

Objective: To evaluate the role of Mycoplasma genitalium, Chlamydia trachomatis, and Neisseria gonorrhoeae in pelvic inflammatory disease (PID) and tubo-ovarian abscess (TOA), and to assess the effectiveness of standard therapy in achieving clinical and microbiological cure.

Design: Multicenter prospective cohort study.

Setting: Three hospitals and one Centre for Sexual Health (CSH) in the Netherlands.

Population: Women ≥ 18 years with clinically diagnosed PID and/or TOA between 2021 and 2023.

Methods: Clinical examination, C-reactive protein (CRP) levels, and vaginal swabs were evaluated at baseline and follow-up. Participants completed a self-reported symptom diary. Antibiotic therapy was prescribed in accordance with Dutch national hospital and CSH guidelines.

Main outcome measures: The primary outcome, clinical cure at Week 4, was defined as the absence of fever and vomiting, CRP < 10 mg/L, and ≥ 70% reduction in symptom score. Microbiological cure was the secondary outcome.

Results: Among 100 women with PID and/or TOA, monoinfections with M. genitalium, C. trachomatis, and N. gonorrhoeae were detected in 4.0%, 6.0%, and 9.0% of cases, respectively; coinfections occurred in 4.0%, while 77.0% tested negative for all three pathogens. By Week 4, M. genitalium and C. trachomatis were cleared, with one case of persistent or recurrent N. gonorrhoeae. Symptom scores declined by 91.3%, with significant CRP reduction. Clinical cure was achieved in 67.3% of participants, with no…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 100 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free